Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Formulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion

dc.contributor.authorMarín-Quintero, D.
dc.contributor.authorFernández Campos, Francisco
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorMontes López, María Jesús
dc.contributor.authorClares Naveros, Beatriz
dc.contributor.authorPozo Carrascosa, Alfonso del
dc.date.accessioned2025-01-31T09:44:32Z
dc.date.available2025-01-31T09:44:32Z
dc.date.issued2013-11-22
dc.date.updated2025-01-31T09:44:32Z
dc.description.abstractABSTRACT: Nystatin (NYS) is a polyene macrolide with broad antifungal spectrum restricted to topical use owing to its toxicity upon systemic administration. The aims of thiswork were the design, development, and optimization ofNYS-loaded lipid emulsion for intravenous administration. A closed circuit system was designed to apply ultrasound during the elaboration of the lipid intravenous emulsions (LIEs). Additionally, a comparison with the commercially available Intralipid R 20% was also performed.Manufacturing conditions were optimized by factorial design. Formulations were evaluated in terms of physicochemical parameters, stability, release profile, and antimicrobial activity. The average droplet size, polydispersity index, zeta-potential, pH, and volume distribution values ranged between 192.5 and 143.0 nm, 0.170 and 0.135, −46 and −44 mV, 7.11 and 7.53, 580 and 670 nm, respectively. The selected NYS-loaded LIE (NYS-LIE54) consisted of soybean oil (30%), soybean lecithin (2%), solutol HSR 15 (4%), and glycerol (2.25%) was stable for at least 60 days. In vitro drug release studies of this formulation suggested a sustained-release profile. Equally, NYS-LIE54 showed the best antimicrobial activity being higher than the free drug. Thus, it could be a promising drug delivery system to treat systemic fungal infections. C 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci Keywords: drug design; nystatin; lipids; emulsion; injectables; surfactants; candida; aspergillus; mathematical model
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec628184
dc.identifier.issn0022-3549
dc.identifier.urihttps://hdl.handle.net/2445/218304
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofVersió postprint del document publicat a:
dc.relation.ispartofJournal of Pharmaceutical Sciences, 2013, vol. 102, num.11, p. 4015-4023
dc.rights(c) The American Pharmacists Association, 2013
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationLípids
dc.subject.classificationEmulsions
dc.subject.otherLipids
dc.subject.otherEmulsions
dc.titleFormulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
166012.pdf
Mida:
848.68 KB
Format:
Adobe Portable Document Format